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Atherosclerotic renovascular disease in United States patients
aged 67 years or older: Risk factors, revascularization, and prog-
nosis.
Background. Although atherosclerotic renovascular disease
is increasingly recognized in chronic kidney disease, few na-
tional level studies have examined its clinical epidemiology.
Methods. Claims data from a 5% random sample of the
United States Medicare population were used to select patients
without atherosclerotic renovascular disease in the 2 years pre-
ceding December 31, 1999 (N = 1,085,250), followed until De-
cember 31, 2001.
Results. The incidence of atherosclerotic renovascular disease
was 3.7 per 1000 patient-years. Major antecedent associations
[P < 0.05, with adjusted hazards ratios (HR) > 1.5] included
chronic kidney disease (adjusted HR 2.54), hypertension (2.42),
peripheral vascular disease (2.00), and atherosclerotic heart
disease (1.70). Adverse event rates after incident atheroscle-
rotic renovascular disease greatly exceeded those in the gen-
eral population (P < 0.0001): atherosclerotic heart disease,
303.9 per 1000 patient-years (vs. 73.5 in the general population);
peripheral vascular disease, 258.6 (vs. 52.2); congestive heart
failure, 194.5 (vs. 56.3); cerebrovascular accident or transient
ischemic attack, 175.5 (vs. 52.9); death, 166.3 (vs. 63.3); and renal
replacement therapy, 28.8 (vs. 1.3). Among atherosclerotic ren-
ovascular disease patients, 16.2% underwent a renal revascular-
ization procedure, percutaneously in 96%. Revascularization
was not associated with renal replacement therapy, congestive
heart failure, or death but was associated with atherosclerotic
heart disease (adjusted HR 1.42) (P = 0.004) and peripheral
vascular disease (adjusted HR 1.38) (P = 0.002).
Conclusion. Atherosclerotic renovascular disease is strongly
associated with cardiovascular disease, both past and future.
Absolute cardiovascular risk exceeds that of renal replacement
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therapy. Renal revascularization is used selectively and shows
inconsistent associations with cardiovascular outcomes, renal
replacement therapy, and death.
Atherosclerotic renovascular disease is an increasingly
recognized cause of chronic kidney disease [1, 2]. It is a
disease of aging, and several studies have shown its strong
association with extrarenal atherosclerotic disease [3–11].
Renal revascularization appears to be increasingly per-
formed in patients with atherosclerotic renovascular dis-
ease, but population rates and prognostic associations are
unknown, and what information is known has been gen-
erated predominantly from single-center studies [12–14]
of individuals presenting for treatment. More recently, it
appears that some patients, not showing consequences of
atherosclerotic renovascular disease, are being identified
during investigations for other cardiovascular conditions.
Options for treatment include surgical revasculariza-
tion, percutaneous angioplasty with or without stenting,
and conservative therapy with management of high blood
pressure and other atherosclerotic risk factors with medi-
cations. The rationale for selection of patients for aggres-
sive or conservative treatment is currently not delineated,
and choice of treatment may be limited by availability of
local surgical or radiologic expertise. The ability to eval-
uate the benefits of either strategy has been limited by
the lack of randomized trials and paucity of prospective
or retrospective comparative cohort data. In particular,
the benefits of renal revascularization, in terms of patient
survival, recovery of kidney function, or delay of kidney
function loss, have not been established. Such data would
be necessary to develop evidence-based, rational guide-
lines.
The prevalence, incidence, and prognostic implications
of atherosclerotic renovascular disease have never been
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Fig. 1. Study design. Abbreviations are: ARVD, atherosclerotic renovascular disease; RRT, renal replacement therapy; CV, cerebrovascular event.
quantified in a general population setting. Furthermore,
the types and frequency of revascularization and the out-
comes associated with revascularization are not known.
The aim of this study was to describe the clinical epidemi-
ology of atherosclerotic renovascular disease in a large,
unselected population, with particular attention paid to
comorbid associations, intervention rates, and prognosis.
METHODS
Objectives
In temporal sequence, the objectives of this study
were to investigate a representative sample of the
elderly general population with regards to (1) preva-
lence of atherosclerotic renovascular disease, (2) cross-
sectional associations of atherosclerotic renovascular dis-
ease, (3) frequency of renal revascularization in prevalent
atherosclerotic renovascular disease, (4) cross-sectional
associations of renal revascularization in prevalent
atherosclerotic renovascular disease, (5) incidence of new
atherosclerotic renovascular disease, (6) antecedent asso-
ciations of incident atherosclerotic renovascular disease,
(7) prognostic associations of incident atherosclerotic
renovascular disease, (8) rates of renal revasculariza-
tion after incident atherosclerotic renovascular disease,
and (9) prognostic associations of renal revascularization
after incident atherosclerotic renovascular disease.
Design
The study design is outlined in Figure 1. Medicare
claims were used to define clinical events, including
atherosclerotic renovascular disease, renal revasculariza-
tion, and comorbid conditions. The prevalent analysis
included patients enrolled in the Medicare program dur-
ing an entry period extending from January 1, 1998, until
December 31, 1999. Patients surviving the entry period
without atherosclerotic renovascular disease were used
in the incident model, with follow-up extending from
January 1, 2000, to December 31, 2001. The prognos-
tic associations of incident atherosclerotic renovascular
disease and renal revascularization after atherosclerotic
renovascular disease were determined with respect to the
development of new-onset cardiovascular events, renal
replacement therapy, and death.
Patients
We used the United States Medicare 5% Denomina-
tor File, a random sample based on health insurance claim
numbers, to identify patients with the following charac-
teristics: (1) continuous enrollment in Part A and Part B
of the Medicare program from January 1, 1998, through
December 31, 1999, with Medicare as the sole primary
payer; (2) residing in the 50 states of United States, the
District of Columbia, Puerto Rico, or the Territories; (3)
age ≥ 65 years on January 1, 1998; (4) alive on December
31, 1999; and (5) not receiving renal replacement therapy
on December 31, 1999.
All data items, with the exception of renal replace-
ment therapy, were identified from Medicare claims. The
underlying International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) and Cur-
rent Procedural Terminology (CPT) codes are shown in
Table 1. Atherosclerotic renovascular disease and renal
revascularization were defined as the presence of at least
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one ICD-9-CM or CPT procedural code. Other clinical
conditions were defined as the presence of one in-patient
hospitalization, skilled nursing facility, or home health
agency code or two outpatient or physician/supplier
codes. Renal replacement therapy was determined by
linking the Medicare 5% Denominator File to the United
States Renal Data System (USRDS) database, which in-
cludes information on all patients entering the renal re-
placement therapy program.
Analysis
In the prevalent analysis, patients with and those with-
out atherosclerotic renovascular disease on December
31, 1999, were compared using v 2 analysis and multiple
logistic regression; revascularization in atherosclerotic
renovascular disease patients was handled similarly.
Follow-up in the incident analysis began on January
1, 2000, and extended until the earliest occurrence of
death, renal replacement therapy, outcome events, or De-
cember 31, 2001. Only new-onset outcome events were
considered in the incident analysis; for example, when
atherosclerotic heart disease was the outcome, the anal-
ysis excluded patients who experienced atherosclerotic
heart disease in the entry period, which ended on Decem-
ber 31, 1999. Cox proportional hazards regression was
used to test the baseline associations of new atheroscle-
rotic renovascular disease. Patients with new atheroscle-
rotic renovascular disease were followed from the time
of diagnosis, while those remaining free of atheroscle-
rotic renovascular disease were followed from January
1, 2000. Associations between these two groups and
outcome events were estimated with 3-monthly interval
Poisson models, because the assumption of temporal con-
stancy of hazards ratios was invalid. Poisson regression
models were also used to estimate the prognostic associ-
ations of renal revascularization concurrent with, or after,
atherosclerotic renovascular disease.
RESULTS
Prevalent analysis
Table 2 shows a cross-sectional comparison of those
with and those without a diagnosis of atherosclerotic
renovascular disease in the 2-year entry period ending
December 31, 1999. Using multiple logistic regression,
the following characteristics were associated (P < 0.05)
with adjusted odds ratios (OR) for atherosclerotic reno-
vascular disease greater than 1: chronic kidney disease
(adjusted OR 4.61), hypertension (adjusted OR 4.31),
peripheral vascular disease (adjusted OR 3.96), aor-
tic aneurysm (adjusted OR 3.38), atherosclerotic heart
disease (adjusted OR 2.45), mesenteric ischemia (ad-
justed OR 2.38), acute renal failure (adjusted OR 1.59),
cerebrovascular accident or transient ischemic attack
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Table 3. Incident analysis: Characteristics of patients with new atherosclerotic renovascular disease (ARVD) between January 1, 2000, and
December 31, 2001a
ARVDb hazards ratio Revascularization hazards ratio
Unadjustedc P valuec Adjustedd P valued Unadjustedc P valuec Adjustedd P valued
Age years
67 to 74 1 — 1 — 1 — 1 —
75 to 84 1.23 (1.17, 1.29) <0.0001 1.00 (0.95, 1.05) 0.9 0.91 (0.82, 1.03) 0.1 0.91 (0.81, 1.02) 0.1
≥ 85 0.74 (0.68, 0.81) <0.0001 0.54 (0.50, 0.59) <0.0001 0.41 (0.31, 0.55) <.0001 0.42 (0.31, 0.56) <.0001
Female gender 0.80 (0.76, 0.84) <0.0001 0.86 (0.82, 0.91) <0.0001 1.05 (0.94, 1.17) 0.4 1.09 (0.97, 1.23) 0.2
Race
White 1 — 1 — 1 — 1 —
Black 0.94 (0.85, 1.02) 0.1 0.79 (0.72, 0.86) <0.0001 0.78 (0.60, 1.00) 0.05 0.76 (0.59, 0.98) 0.03
Other 0.65 (0.56, 0.75) <0.0001 0.60 (0.52, 0.69) <0.0001 0.73 (0.48, 1.10) 0.1 0.72 (0.48, 1.09) 0.1
Acute kidney disease 4.58 (3.99, 5.26) <0.0001 1.08 (0.92, 1.25) 0.3 0.99 (0.70, 1.40) 0.9 1.09(0.75, 1.58) 0.7
Chronic kidney disease 5.44 (5.03, 5.88) <0.0001 2.54 (2.32, 2.78) <0.0001 0.94 (0.77, 1.15) 0.5 0.93(0.75, 1.16) 0.5
Diabetes mellitus 2.13 (2.02, 2.23) <0.0001 1.28 (1.22, 1.35) <0.0001 1.04 (0.92, 1.18) 0.5 0.99 (0.87, 1.12) 0.9
Hypertension 3.38 (3.20, 3.58) <0.0001 2.42 (2.28, 2.57) <0.0001 1.33 (1.15, 1.55) 0.0002 1.32 (1.13, 1.54) 0.0006
Atherosclerotic heart disease 2.92 (2.79, 3.06) <0.0001 1.70 (1.61, 1.79) <0.0001 1.21 (1.08, 1.35) 0.001 1.23 (1.08, 1.39) 0.002
Congestive heart failure 2.38 (2.26, 2.51) <0.0001 1.12 (1.05, 1.19) 0.0004 1.00 (0.88, 1.14) 1.0 1.00 (0.86, 1.16) 1.0
CVA/TIA 2.47 (2.34, 2.60) <0.0001 1.36 (1.29, 1.44) <0.0001 1.15 (1.01, 1.31) 0.03 1.12 (0.98, 1.28) 0.1
Peripheral vascular disease 3.26 (3.10, 3.43) <0.0001 2.00 (1.90, 2.11) <0.0001 1.02 (0.90, 1.15) 0.8 0.97 (0.85, 1.11) 0.7
COPD 1.61 (1.52, 1.70) <0.0001 1.02 (0.96, 1.08) 0.6 0.99 (0.86, 1.14) 0.9 0.97 (0.84, 1.12) 0.7
Gastrointestinal bleeding 1.69 (1.56, 1.83) <0.0001 1.03 (0.95, 1.12) 0.5 0.87 (0.71, 1.06) 0.2 0.92 (0.74, 1.14) 0.5
Hepatic disease 1.15 (0.90, 1.47) 0.3 0.71 (0.56, 0.91) 0.007 0.36 (0.14, 0.96) 0.04 0.37 (0.14, 0.98) 0.05
Cancer 1.25 (1.18, 1.32) <0.0001 1.04 (0.98, 1.10) 0.2 0.88 (0.76, 1.01) 0.07 0.90 (0.78, 1.04) 0.2
Anemia 1.78 (1.69, 1.88) <0.0001 1.05 (0.99, 1.12) 0.09 0.85 (0.74, 0.98) 0.02 0.85 (0.73, 0.99) 0.03
Mesenteric ischemia 2.60 (1.92, 3.53) <0.0001 1.35 (0.99, 1.83) 0.05 0.91 (0.41, 2.02) 0.8 0.95 (0.42, 2.13) 0.9
Aortic aneurysm 2.91 (2.38, 3.56) <0.0001 1.12 (0.91, 1.37) 0.3 0.76 (0.43, 1.34) 0.3 0.74 (0.42, 1.30) 0.3
Abbreviations are: COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular accident or transient ischemic attack.
aN = 1,084,963. Excluded were 287 patients because they had a revascularization procedure code alone or before a diagnosis of atherosclerotic renovascular disease.
bAtherosclerotic renovascular disease includes those with or without revascularization.
cUnadjusted Cox regression.
dUsing a Cox regression model, including all variables shown in the first column. Reference groups: age 67 to 74 years, male gender, white race, no comorbid conditions.
(adjusted OR 1.58), anemia (adjusted OR 1.19), and can-
cer (adjusted OR 1.09). Characteristics associated with
adjusted OR less than 1 were age ≥85 years (adjusted
OR 0.44 compared to age 67 to 74 years), race catego-
rized as “other” (adjusted OR 0.64 compared to white
race), black race (adjusted OR 0.66 compared to white
race), hepatic disease (adjusted OR 0.76), age 75 to 84
years (adjusted OR 0.86 compared to age 67 to 74 years),
diabetes mellitus (adjusted OR 0.89), and gastrointestinal
bleeding (adjusted OR 0.89).
Of the 5875 patients with atherosclerotic renovascu-
lar disease, 961 (16.4%) had undergone a renal revas-
cularization procedure at the time of atherosclerotic
renovascular disease diagnosis, or afterwards. Percuta-
neous procedures were used in 92% of cases, surgical in
11%, and both in 3%. Table 2 also shows a cross-sectional
comparison of atherosclerotic renovascular disease pa-
tients dichotomized by performance of a revasculariza-
tion procedure. Using multiple logistic regression, the
following characteristics were associated with adjusted
OR for revascularization greater than 1: hypertension
(adjusted OR 3.97), atherosclerotic heart disease (ad-
justed OR 1.90), peripheral vascular disease (adjusted
OR 1.82), aortic aneurysm (adjusted OR 1.47), chronic
kidney disease (adjusted OR 1.36), acute renal failure
(adjusted OR 1.19), and female gender (adjusted OR 1.17
compared to male). Age ≥ 85 years (adjusted OR 0.42
compared to age 67 to 74 years), black race (adjusted
OR 0.55 compared to white race), chronic obstructive
pulmonary disease (adjusted OR 0.79), cancer (adjusted
OR 0.79), and age 75 to 84 years (adjusted OR 0.86 com-
pared to age 67 to 74 years) were associated with adjusted
OR less than 1.
Incident analysis
The incident analysis included 1,085,250 patients with-
out atherosclerotic renovascular disease in the preceding
2 years. The overall incidence of atherosclerotic renovas-
cular disease was 3.7 per 1000 patient-years. Table 3 shows
hazards ratios for incident atherosclerotic renovascular
disease. The following characteristics were associated
with adjusted hazards ratios (HR) for atherosclerotic ren-
ovascular disease greater than 1: chronic kidney disease
(adjusted HR 2.54), hypertension (adjusted HR 2.42), pe-
ripheral vascular disease (adjusted HR 2.00), atheroscle-
rotic heart disease (adjusted HR 1.70), cerebrovascular
accident or transient ischemic attack (adjusted HR 1.36),
mesenteric ischemia (adjusted HR 1.35), diabetes mel-
litus (adjusted HR 1.28), aortic aneurysm (adjusted HR
1.12), and congestive heart failure (adjusted HR 1.12).
Adjusted HR was less than 1 for age ≥ 85 years (adjusted
298 Kalra et al: Atherosclerotic renovascular disease
RRT Death AHR=1
18
15
12
9
6
3
0
Ad
jus
ted
 ha
za
rds
 ra
tio
2421181512963
Months
A
12
9
6
3
0
Ad
jus
ted
 ha
za
rds
 ra
tio
2421181512963
Months
B CVA/TIA PVD AHR=1
CHF ASHD AHR=1
12
9
6
3
0
Ad
jus
ted
 ha
za
rds
 ra
tio
3 6 9 12 15 18 21 24
Months
C
Fig. 2. Interval Poisson analysis. Adjusted
hazards ratios (AHR) and 95% confidence
intervals, comparing patients with incident
atherosclerotic renovascular disease to the
overall population. Adjustment was made for
all variables shown in the first column of Table
2. (A) Renal replacement therapy (RRT) and
death. (B) Cerebrovascular accident or tran-
sient ischemic attack (CVA/TIA) and periph-
eral vascular disease (PVD). (C) Congestive
heart failure (CHF) and atherosclerotic heart
disease (ASHD).
HR 0.54 compared to age 67 to 74 years), race categorized
as “other” (adjusted HR 0.60 compared to white race),
hepatic disease (adjusted HR 0.71), black race (adjusted
HR 0.79 compared to white race), and female gender (ad-
justed HR 0.86 compared to male).
Of 7434 incident atherosclerotic renovascular disease
patients, 1204 (16.2%) underwent a renal revascular-
ization procedure at the time of atherosclerotic reno-
vascular disease diagnosis, or afterwards. Percutaneous
procedures were used in 95% of cases, surgical in 6%, and
both in 1%. Table 3 also shows hazards ratios for revascu-
larization according to patient characteristics. Using ad-
justed Cox regression, the following characteristics were
associated with adjusted HR for revascularization greater
than 1: hypertension (adjusted HR 1.32), atherosclerotic
heart disease (adjusted HR 1.23), and cerebrovascular
accident or transient ischemic attack (adjusted HR 1.12).
Hepatic disease (adjusted HR 0.37), age ≥85 years (ad-
justed HR 0.42 compared to age 67 to 74 years), black race
(adjusted HR 0.76 compared to white race), and anemia
(adjusted HR 0.85) were associated with adjusted HR
less than 1.
When the time of diagnosis was used as starting point,
the rates of new-onset clinical events after atheroscle-
rotic renovascular disease were as follows: atheroscle-
rotic heart disease, 303.9 per 1000 patient-years (vs.
73.5 in the general population); peripheral vascular dis-
ease, 258.6 (vs. 52.2); congestive heart failure, 194.5 (vs.
56.3); cerebrovascular accident or transient ischemic at-
tack, 175.5 (vs. 52.9); death, 166.3 (vs. 63.3); and renal
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replacement therapy, 28.8 (vs. 1.3). Figure 2 shows ad-
justed HR for each of these events, comparing those with
incident atherosclerotic renovascular disease to the over-
all population, using 3-month interval Poisson regression
models. Atherosclerotic renovascular disease was associ-
ated with each event, in each interval up to 15 months
(P < 0.0001 for each comparison). Regarding the six out-
come variables in the next three intervals, while point
estimates were consistently greater than 1, statistical sig-
nificance was present for 9 of the 18 HRs.
Renal revascularization (treated as a conditional event
that could occur at the same time as, or after, atheroscle-
rotic renovascular disease diagnosis) was associated with
the following adjusted HRs: atherosclerotic heart disease,
1.42 (95% CI 1.12 to 1.81) (P = 0.004); peripheral vascu-
lar disease, 1.38 (95% CI 1.13 to 1.69) (P = 0.002); renal
replacement therapy, 1.02 (95% CI 0.69 to 1.50) (P = 0.9);
congestive heart failure, 0.89 (95% CI 0.71 to 1.10) (P =
0.3); and death, 0.84 (95% CI 0.70 to 1.01) (P = 0.06).
DISCUSSION
Symptomatic disease of the extrarenal vasculature, hy-
pertension, and chronic kidney disease were the fac-
tors showing the largest association with both prevalent
and incident atherosclerotic renovascular disease. New
episodes of atherosclerotic renovascular disease were as-
sociated with very high cardiovascular morbidity and
mortality rates. Renal revascularization was attempted
in a minority of patients and was more likely to be used
in the presence of atherosclerotic heart disease and hy-
pertension and less likely in older and black patients. In
terms of prognosis, revascularization showed inconsistent
association patterns with regard to the suite of outcomes
studied, including cardiovascular events, renal replace-
ment therapy, and death.
Our findings suggest that the prevalence of clini-
cally manifest atherosclerotic renovascular disease in
the United States Medicare population is approximately
0.5% overall and 5.5% in those with chronic kidney
disease. Atherosclerotic renovascular disease is often
asymptomatic, and so this study is likely to underestimate
the true disease burden. One community-based screening
study, for example, reported that 6.8% of elderly subjects
had atherosclerotic renovascular disease [15]. The preva-
lence data in this study are likely to underestimate the
true prevalence of the disease because only those with
symptomatic disease were included. Those with asymp-
tomatic disease and those who died soon after reaching
symptomatic stages (an unfortunately large proportion)
were not considered. The macrovascular associations of
atherosclerotic renovascular disease have been described
in many previous studies [3–11], but these have usually
been in selected groups of patients who already had vas-
cular disease (e.g., performance of aortography in pa-
tients being investigated for atherosclerotic heart disease
[6–8] or peripheral vascular disease [3, 4]). The very fre-
quent cosegregation of atherosclerotic renovascular dis-
ease with atherosclerotic heart disease, congestive heart
failure, cerebrovascular disease, and peripheral vascular
disease, seen in our study, parallels these findings. Also,
these relationships may in part reflect how patients were
selected for renal artery imaging.
The prevalence and incidence of cardiovascular disease
in atherosclerotic renovascular disease patients were no-
tably high, and it is plausible that macrovascular events
were responsible for much of the 2.6-fold higher mor-
tality rates in these patients. In absolute terms, cardio-
vascular risk was considerably higher than that of renal
replacement therapy. Previous studies have shown that
up to 25% of elderly end-stage renal disease (ESRD) pa-
tients may have atherosclerotic renovascular disease [16];
it has been suggested that atherosclerotic renovascular
disease may often be an innocent bystander in a process
where intrarenal pathology is caused by the same factors
that lead to widespread vascular disease [17]. Such a pro-
cess could partly explain why clinical trials have failed to
show any renal functional benefit of revascularization in
atherosclerotic renovascular disease [18–20].
Approximately one in six atherosclerotic renovascular
disease patients underwent renal revascularization, and
the vast majority of interventions were via the percuta-
neous route. Although the specific rationale for revas-
cularization in each patient could not be determined in
this study, selection for atherosclerotic renovascular dis-
ease appeared to be a nonrandom process and may have
been influenced by factors such as age, race, and comor-
bid vascular disease. In terms of subsequent outcomes,
it is difficult to reconcile higher rates of atherosclerotic
heart disease and peripheral vascular disease with neu-
tral associations with lower death and renal replacement
therapy rates, suggesting that associations of renal revas-
cularization should be interpreted cautiously. The finding
that revascularization had a neutral association with re-
nal functional outcome is consistent with other studies. To
date, four randomized controlled trials of percutaneous
renal revascularization have been performed in patients
with atherosclerotic renovascular disease [18–21], and al-
though modest benefits in blood pressure control were
demonstrated in three [18–20], none has shown benefit
in terms of renal functional outcome. However, patient
numbers included in each of these trials were small, and
none were adequately powered to detect differences in
renal function. Other observational studies suggest that
up to 75% of atherosclerotic renovascular disease pa-
tients fail to derive renal functional benefit from revascu-
larization [22–24] and that renal outcomes in atheroscle-
rotic renovascular disease are related more to the severity
of proteinuria [25] and renal histopathologic injury [26]
than to severity of proximal renal arterial narrowing
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[27–29]. This hypothesis is supported by Doppler ultra-
sound studies showing that atherosclerotic renovascular
disease patients with high renal resistive indices, due to
severe intrarenal damage, are unlikely to benefit from
revascularization [30]. Nevertheless, certain subgroups
of patients with atherosclerotic renovascular disease are
more likely to have a favorable outcome (such as stabi-
lization of previously deteriorating renal function or im-
provement from baseline renal function) after revascular-
ization. These include patients with a solitary functioning
kidney [31] or with severe bilateral renal artery stenosis
[32], and, more generally, those having reasonable preser-
vation of renal function (creatinine <3.0 mg/dL) before
the procedure [24].
Limitations of this study should be pointed out. Our
study was retrospective and used administrative claims
to define the study population and their outcomes. The
definition of prior comorbidity was based on the pre-
ceding 2 years, so that cross-sectional associations be-
tween vascular disease and atherosclerotic renovascular
disease may have been underestimated. The validity of
using atherosclerotic renovascular disease claims to make
a diagnosis of atherosclerotic renovascular disease could
not be ascertained in this study. Previous studies have
suggested that diagnoses based on administrative claims
tend to be specific, but insensitive [33]. Atherosclerotic
renovascular disease may have been an incidental find-
ing during the diagnostic workup (especially by angiogra-
phy) of symptomatic disease of other vascular beds. Such
a scenario could lead to an artificially inflated estimate of
the association between atherosclerotic renovascular dis-
ease and nonrenal vascular diseases. A similar cautionary
note should be applied to the apparently grim prognosis
of atherosclerotic renovascular disease, as HRs for car-
diovascular events were especially high immediately af-
ter atherosclerotic renovascular disease diagnosis. Thus,
our study, which suggests that moderate incidence rates
and poor survival rates lead to low prevalence rates, is an
imperfect vehicle for defining the utility of screening in
atherosclerotic renovascular disease. Medicare data are
almost exclusive to patients aged 65 years or older and
should not be generalized to younger populations. In this
regard, it is worth pointing out that both the prevalence
and the incidence of atherosclerotic renovascular disease
were inversely related to age in our study.
Despite its limitations, we feel that this study provides
clinically useful information. Patients with atheroscle-
rotic renovascular disease appear to be at a much greater
risk of atherosclerotic vascular disease and death than
they are of progressing to renal replacement therapy. This
suggests that cardioprevention should receive at least as
much attention as prevention of renal replacement ther-
apy in affected patients. Therapeutic trials in both are-
nas are warranted. Gratifyingly, two ongoing trials from
Europe [the Angioplasty and Stent for Renal Artery
Lesions (ASTRAL) trial [34] and the Benefit of Stent
Placement and Blood Pressure and Lipid-Lowering for
the Prevention of Progression of Renal Dysfunction
Caused by Atherosclerotic Ostial Stenosis of the Renal
Artery (STAR) trial [35]] and one from the United States
[the Cardiovascular Outcomes in Renal Atherosclerotic
Lesions (CORAL) trial [36]], have the potential to clarify
some of the major areas of uncertainty concerning indi-
cations for, and outcomes after, renal revascularization
in patients with atherosclerotic renovascular disease.
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